- Page 1: National Toxicology Program U.S. De
- Page 4 and 5: [This page inTenTionally lefT blank
- Page 6 and 7: [This page inTenTionally lefT blank
- Page 8 and 9: NTP.will.transmit.the.NTP-CERHR.<st
- Page 10: National Toxicology Program U.S. De
- Page 15 and 16: nTp brief tainers.with.internal.epo
- Page 17 and 18: Population Adult General. Populatio
- Page 19 and 20: Table 3. Blood and Breast Milk Biom
- Page 21 and 22: Figure 2b. The weight of evidence t
- Page 23 and 24: in.considering.the.biological.plaus
- Page 25 and 26: isphenol.A.as.efficiently.as.adult.
- Page 27 and 28: isphenol.A..For.example,.this.raise
- Page 29 and 30: laboRaToRy aNImal STudIeS In.contra
- Page 31 and 32: of.normal.sex-based.differences.bet
- Page 33 and 34: death.(168),.synaptic.plasticity.(1
- Page 35 and 36: gland.carcinogen.or.that.bisphenol.
- Page 37 and 38: understand.the.possible.long-term.c
- Page 39 and 40: strategies.to.improve.the.sensitivi
- Page 41 and 42: • • Howdeshell.et.al. (55).repo
- Page 43 and 44: and.cystic.endometrial.hyperplasia.
- Page 45 and 46: cutaneous. injection. 20 . vom. Saa
- Page 47 and 48: are CurrenT exposures To bisphenol
- Page 49 and 50: w/day;.95th.percentiles.0.289.-.0.2
- Page 51 and 52: nTp ConClusions The.NTP.reached.the
- Page 53 and 54: appendix a: inTerpreTaTion of blood
- Page 55 and 56: µg/kg.bw/day.based.on.the.assumpti
- Page 57 and 58: concentrations.from.maternal,.fetal
- Page 59 and 60: 12.. Padmanabhan. V,. Siefert. K,.
- Page 61 and 62:
In..Research.Triangle.Park,.NC:.RTI
- Page 63 and 64:
65.. Alonso-Magdalena. P,. Laribi.
- Page 65 and 66:
91.. Calabrese.EJ,.Baldwin.LA.(2003
- Page 67 and 68:
Thyroid.Function.in.Juvenile.Female
- Page 69 and 70:
droxylase.immunoreactivity..76:423.
- Page 71 and 72:
stanceschimiques.gc.ca/challenge-de
- Page 73 and 74:
Watanabe.H,.Ohta.Y,.Iguchi.T.(2006)
- Page 75 and 76:
226..vom. Saal. FS,. Cooke. PS,. Bu
- Page 77 and 78:
solid.phase.extraction-high.perform
- Page 79 and 80:
appendix i. nTp-Cerhr bisphenol a e
- Page 81 and 82:
158 CHAPIN ET AL. the CERHR Core Co
- Page 83 and 84:
160 CHAPIN ET AL. referred to as 4,
- Page 85 and 86:
162 CHAPIN ET AL. concentrations in
- Page 87 and 88:
164 CHAPIN ET AL. Food (no. sampled
- Page 89 and 90:
166 CHAPIN ET AL. Table 6 Continued
- Page 91 and 92:
168 CHAPIN ET AL. comparison of the
- Page 93 and 94:
170 CHAPIN ET AL. Table 8 Urinary C
- Page 95 and 96:
172 CHAPIN ET AL. the blood of male
- Page 97 and 98:
174 CHAPIN ET AL. Table 11 Bispheno
- Page 99 and 100:
176 CHAPIN ET AL. Table 13 Summarie
- Page 101 and 102:
178 CHAPIN ET AL. Table 15 Estimate
- Page 103 and 104:
180 CHAPIN ET AL. Table 17 Maximum
- Page 105 and 106:
182 CHAPIN ET AL. 2.0 GENERAL TOXIC
- Page 107 and 108:
184 CHAPIN ET AL. fetuses (3.572.7
- Page 109 and 110:
186 CHAPIN ET AL. Secondary sources
- Page 111 and 112:
188 CHAPIN ET AL. Table 25 Maternal
- Page 113 and 114:
190 CHAPIN ET AL. Table 27 Bispheno
- Page 115 and 116:
192 CHAPIN ET AL. Table 31 Qualitat
- Page 117 and 118:
194 CHAPIN ET AL. Table 33 Toxicoki
- Page 119 and 120:
196 CHAPIN ET AL. Table 36 Toxicoki
- Page 121 and 122:
198 CHAPIN ET AL. appeared to occur
- Page 123 and 124:
200 CHAPIN ET AL. Table 43 Biliary
- Page 125 and 126:
202 CHAPIN ET AL. suggesting that 4
- Page 127 and 128:
204 CHAPIN ET AL. low following ora
- Page 129 and 130:
206 CHAPIN ET AL. scaling and speci
- Page 131 and 132:
208 CHAPIN ET AL. 60-100% in each d
- Page 133 and 134:
210 CHAPIN ET AL. related. No histo
- Page 135 and 136:
212 CHAPIN ET AL. Table 52 Continue
- Page 137 and 138:
214 CHAPIN ET AL. Model and exposur
- Page 139 and 140:
216 CHAPIN ET AL. Model and exposur
- Page 141 and 142:
218 Model and exposure Husbandry a
- Page 143 and 144:
220 CHAPIN ET AL. Table 54 Differen
- Page 145 and 146:
222 CHAPIN ET AL. Table 56 Anti-And
- Page 147 and 148:
224 Table 57 In Vitro Genetic Toxic
- Page 149 and 150:
226 CHAPIN ET AL. Table 58 In Vivo
- Page 151 and 152:
228 CHAPIN ET AL. Table 59 Developm
- Page 153 and 154:
230 CHAPIN ET AL. Table 62 Toxicoki
- Page 155 and 156:
232 CHAPIN ET AL. Table 64 Tissue R
- Page 157 and 158:
234 CHAPIN ET AL. Table 68 Toxicoki
- Page 159 and 160:
236 CHAPIN ET AL. treatment conditi
- Page 161 and 162:
238 CHAPIN ET AL. clinical signs, b
- Page 163 and 164:
240 CHAPIN ET AL. Table 71 Benchmar
- Page 165 and 166:
242 CHAPIN ET AL. group, 5 from 1 l
- Page 167 and 168:
244 CHAPIN ET AL. least significant
- Page 169 and 170:
246 CHAPIN ET AL. group was a reduc
- Page 171 and 172:
248 CHAPIN ET AL. 100-151 g for fem
- Page 173 and 174:
250 CHAPIN ET AL. 3.2.3.2 Developme
- Page 175 and 176:
252 CHAPIN ET AL. weights, bispheno
- Page 177 and 178:
254 CHAPIN ET AL. 120 mg/kg bw/day
- Page 179 and 180:
256 CHAPIN ET AL. comparisons condu
- Page 181 and 182:
258 CHAPIN ET AL. the findings of t
- Page 183 and 184:
260 CHAPIN ET AL. analyzed.] Anogen
- Page 185 and 186:
262 CHAPIN ET AL. purposeful confou
- Page 187 and 188:
264 CHAPIN ET AL. increased lordosi
- Page 189 and 190:
266 CHAPIN ET AL. that there was a
- Page 191 and 192:
268 CHAPIN ET AL. duration of adver
- Page 193 and 194:
270 CHAPIN ET AL. doses of potent e
- Page 195 and 196:
272 CHAPIN ET AL. Table 74 Effects
- Page 197 and 198:
274 CHAPIN ET AL. reproductive orga
- Page 199 and 200:
276 CHAPIN ET AL. tyrosine-hydroxly
- Page 201 and 202:
278 CHAPIN ET AL. include small sam
- Page 203 and 204:
280 CHAPIN ET AL. males/group. [It
- Page 205 and 206:
282 CHAPIN ET AL. termination, whic
- Page 207 and 208:
284 CHAPIN ET AL. provided a reliab
- Page 209 and 210:
286 CHAPIN ET AL. grooming, and out
- Page 211 and 212:
288 CHAPIN ET AL. method of oral do
- Page 213 and 214:
290 CHAPIN ET AL. reared by their d
- Page 215 and 216:
292 CHAPIN ET AL. has been informed
- Page 217 and 218:
294 CHAPIN ET AL. buffered paraform
- Page 219 and 220:
296 CHAPIN ET AL. unit. Further, th
- Page 221 and 222:
298 CHAPIN ET AL. PND 21 and housed
- Page 223 and 224:
300 CHAPIN ET AL. Tando et al. (200
- Page 225 and 226:
302 CHAPIN ET AL. Purina Certified
- Page 227 and 228:
304 CHAPIN ET AL. high-doses of bis
- Page 229 and 230:
306 CHAPIN ET AL. born to those dam
- Page 231 and 232:
308 CHAPIN ET AL. average weight we
- Page 233 and 234:
310 CHAPIN ET AL. study authors con
- Page 235 and 236:
312 CHAPIN ET AL. used for extracti
- Page 237 and 238:
314 CHAPIN ET AL. jar, and there we
- Page 239 and 240:
316 CHAPIN ET AL. of testes and com
- Page 241 and 242:
318 CHAPIN ET AL. differentiation o
- Page 243 and 244:
320 CHAPIN ET AL. Table 81 Summary
- Page 245 and 246:
322 CHAPIN ET AL. Table 82 Continue
- Page 247 and 248:
324 CHAPIN ET AL. Table 84 Summary
- Page 249 and 250:
326 CHAPIN ET AL. Table 85 Summary
- Page 251 and 252:
328 CHAPIN ET AL. 600 mg/kg bw/day)
- Page 253 and 254:
330 CHAPIN ET AL. (Nagao et al., 19
- Page 255 and 256:
332 CHAPIN ET AL. antinuclear antib
- Page 257 and 258:
334 CHAPIN ET AL. least 6 animals.
- Page 259 and 260:
336 CHAPIN ET AL. Utility (Adequacy
- Page 261 and 262:
338 CHAPIN ET AL. stomach weight wa
- Page 263 and 264:
340 CHAPIN ET AL. Schirling et al.
- Page 265 and 266:
342 CHAPIN ET AL. Endpoint Table 88
- Page 267 and 268:
344 CHAPIN ET AL. different diets b
- Page 269 and 270:
346 CHAPIN ET AL. with 40 mg vitami
- Page 271 and 272:
348 CHAPIN ET AL. the bisphenol A v
- Page 273 and 274:
350 CHAPIN ET AL. and determining t
- Page 275 and 276:
352 CHAPIN ET AL. expression [to B6
- Page 277 and 278:
354 CHAPIN ET AL. indicated] at 0 (
- Page 279 and 280:
356 CHAPIN ET AL. concentrations us
- Page 281 and 282:
358 CHAPIN ET AL. animals were non-
- Page 283 and 284:
360 CHAPIN ET AL. following adjustm
- Page 285 and 286:
362 CHAPIN ET AL. Table 94 Treatmen
- Page 287 and 288:
364 CHAPIN ET AL. Table 97 Effects
- Page 289 and 290:
366 CHAPIN ET AL. Table 99 Treatmen
- Page 291 and 292:
368 CHAPIN ET AL. Therefore the NTP
- Page 293 and 294:
370 CHAPIN ET AL. weeks before mati
- Page 295 and 296:
372 CHAPIN ET AL. Table 100 Summary
- Page 297 and 298:
374 Table 101 Summary of High Utili
- Page 299 and 300:
376 Table 102 Summary of Limited Ut
- Page 301 and 302:
378 CHAPIN ET AL. Table 103 Summary
- Page 303 and 304:
380 CHAPIN ET AL. from other suppli
- Page 305 and 306:
382 CHAPIN ET AL. U.S. populations.
- Page 307 and 308:
384 CHAPIN ET AL. 10. Critical desi
- Page 309 and 310:
386 CHAPIN ET AL. Engel SM, Levy B,
- Page 311 and 312:
388 CHAPIN ET AL. alpha and beta ex
- Page 313 and 314:
390 CHAPIN ET AL. Murray TJ, Maffin
- Page 315 and 316:
392 CHAPIN ET AL. Ryan BC, Vandenbe
- Page 317 and 318:
394 CHAPIN ET AL. Thomas P, Dong J.
- Page 319 and 320:
[This page inTenTionally lefT blank
- Page 321:
appendix iii. publiC CommenTs and p